Previously submitted to: Journal of Medical Internet Research (no longer under consideration since Dec 15, 2021)
Date Submitted: May 31, 2021
Open Peer Review Period: May 31, 2021 - Jul 26, 2021
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The Effectiveness of the Digital Care Platform CMyLife for Patients With Chronic Myeloid Leukemia: Patient-Preference Trial
ABSTRACT
Background:
The two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring, but both are still suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients. CMyLife aims to provide these patients with tools and knowledge to have more control over their disease process and improve medication compliance and molecular monitoring. This could eventually lead to an increased quality of life and the opportunity of hospital-free care.
Objective:
The aim of this study was to explore the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring, and quality of life.
Methods:
The effectiveness of CMyLife was explored using a patient-preference trial. Participants received a written baseline questionnaire by mail. Upon completion of the baseline questionnaire, participants actively used (intervention group) or did not actively use (questionnaire group) the CMyLife platform for at least six months, after which they completed the post-intervention questionnaire. The scores between the intervention group and the questionnaire group were compared with regard to the within-subject change between baseline and post-measurement using Generalized Estimating Equation models.
Results:
At baseline, 33 patients were enrolled in the questionnaire group and 75 in the intervention group. After six months, 29 patients filled in the post-intervention questionnaire in the questionnaire group and 57 patients filled in the post-intervention questionnaire in the intervention group. Online health information knowledge improved significantly when actively using CMyLife and patients felt more empowered. No significant improvements were found regarding medication compliance and molecular monitoring, which were already outstanding. However, self-reported effectiveness showed that patients experienced that using CMyLife improved their medication compliance and helped them to oversee their molecular monitoring. Patients using CMyLife reported more symptoms but were better able to manage these.
Conclusions:
In the future, an iterative process of assessing patients’ needs and further adjustment of CMyLife is required, to keep care patient-centered and put patients in lead of their disease process. Since hospital-free care has shown to be feasible in time of the COVID-19 pandemic, eHealth-based innovations such as CMyLife could be a solution to maintain the quality of care and make current oncological health care services more sustainable. Clinical Trial: ClinicalTrials.gov NCT04595955
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.